{"disease":{"id":"her2-positive-advanced-gastric-cancer","name":"her2 positive advanced gastric cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05993234","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","phase":"","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":false},{"nct_id":"NCT06157892","title":"A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":172,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT05348161","title":"Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT05640830","title":"Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":47,"lead_sponsor_name":"Kangbuk Samsung Hospital","has_results":false},{"nct_id":"NCT04550494","title":"Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06023758","title":"Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Peking University","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}